Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of IPI-504 in Combination With Trastuzumab in Patients With Pretreated, Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Sponsor: Infinity Pharmaceuticals, Inc.
Terminated
Limited efficacy response observed during interim analysis.
Other terminated trials from Infinity Pharmaceuticals, Inc.
- Advanced Malignancies · Phase PHASE1 · Jul 2011
- Hematologic Malignancies · Phase PHASE1 · Jul 2011
- Metastatic Melanoma · Phase PHASE2 · Oct 2009
More terminations from Infinity Pharmaceuticals, Inc.
This PHASE2 trial investigates Breast Cancer and Cancer of the Breast and is currently terminated or withdrawn. Infinity Pharmaceuticals, Inc. leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Infinity Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .